Robert Ore, MD
Gynecologic Oncology · Lacey, WANPI 1326213794
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (37.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 83.9% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $2,737, more than ten times the $11 reported in 2020.
Across 21 payments — averaging $254.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Eisai Inc.$279
- Pfizer$261
- AstraZeneca$126
- GSK$102
- Myriad Genetic Laboratories, Inc.$45
- plus $47 from 2 others
What the payments were for
- Travel & lodging$1,80334%
- Food & beverage$1,52028%
- Education$2,00037%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $4,478 |
| Eisai Inc. | 3 | $279 |
| Pfizer | 2 | $261 |
| AstraZeneca | 2 | $126 |
| GSK | 1 | $102 |
| Myriad Genetic Laboratories, Inc. | 1 | $45 |
| Immunogen, Inc. | 1 | $36 |
| Avanos Medical | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,438
- TIVDAK$261
- LENVIMA$221
- JEMPERLI$102
How this compares
$5,338 in reported general payments places this provider in the 80th percentile of 36 gynecologic oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 45 | $472 |
| Ondansetron OdtOndansetron | 37 | $466 |
| Dexamethasone | 59 | $353 |
| Ibuprofen | 31 | $213 |
| Ondansetron Hcl | 33 | $201 |
| Olanzapine | 45 | $126 |
| Methocarbamol | 16 | $86 |
| Tramadol Hcl | 36 | $49 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Lacey
- John O'BoyleLacey$3K
- Chirag ShahSeattle$732K
- Fernanda MusaSeattle$120K
- Bobbie RimelSeattle$41K
- Nicole FlemingSeattle$20K
- Kristin TaylorEverett$12K
- Renata UrbanSeattle$7K
- Christopher BreedPuyallup$5K
- Amy BrockmeyerSeattle$4K
- Elizabeth GrosenSpokane$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.